Effect of initial recurrence site on the prognosis of different tissue types of non-small cell lung cancer: a retrospective cohort study

PURPOSE: To explore the correlation between the initial recurrence site and survival after recurrence (PRS) in non-small cell lung cancer (NSCLC). METHODS: We collected 588 stages I–III NSCLC patients with recurrence after radical resection in Yunnan Cancer Hospital from January 2013 to December 2018. We used Kaplan–Meier survival curves to compare PRS in patients with different site recurrences. The univariate and multivariate Cox proportional hazard models were used to analyze the impact of the initial recurrence site on PRS. RESULTS: The recurrence site included the lung (n = 109), brain (n = 113), bone (n = 79), abdomen (n = 28), pleura (n = 24), lymph node (n = 81), and multisite (n = 154). In the total population, patients with multisite recurrence had substantially worse PRS (24.8 months, 95% confidence interval [CI]: 17.46–32.20) than that of patients without multiple sites recurrence (42.2 months, 95% CI 32.24–52.10) (P = 0.026). However, patients with lung recurrence had better RFS (63.1 months, 95% CI 51.13–74.00) than those who did not (31.0 months, 95% CI 25.10–36.96) (P < 0.001). In adenocarcinoma, patients with pleural recurrence had substantially worse PRS (21.3 months, 95% CI 15.07–27.46) than that of patients without pleural recurrence (46.9 months, 95% CI 35.07–58.80) (P = 0.031). Multivariate Cox proportional hazards regression analysis revealed that lung recurrence (HR 0.58, 95% CI 0.40–0.82; P = 0.003) was independent protective prognostic factor for PRS in the total population, while pleural recurrence (HR 2.18, 95% CI 1.14–4.17; P = 0.018) was independent adverse prognostic factors for PRS in adenocarcinoma patients. CONCLUSION: The initial recurrence site was associated with PRS in NSCLC patients. Identification of recurrence sites could guide the subsequent treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03252-x.